Summary
Medsensio was founded in 2017 as a spinout from a research project in health data analysis at UiT the Arctic University of Norway, classifying lung and heart sounds and additional parameters from Norway's largest population study known as the Tromsø study.
We saw an opportunity how AI and machine learning could be used to successfully analyze large amounts of data at expert-level performance. And we saw how remote patient monitoring of chronic lung and heart patients, producing large amounts of data, could benefit from technology like ours.
Medsensio offers a digital care solution which brings AI into screening, monitoring and predictions in chronic lung and heart disease management for improving patient outcomes and reducing cost. Our product is now ready for regulatory compliance under MDR and we are preparing for market launch in 2023.
WomenTechEU will provide access to mentoring and networks to support our female CEO in building a strong and gender balanced team, leading it through the early market phase. Furthermore, it will make Medsensio better prepared for realising its market and growth potential:
• Boosting our expertise in handling negotiations and closing accounts for establishing partnerships, profiling potential customers for an efficient sales process, refining our marketing and sales tactics;
• Expanding collaboration and streamlining communication in the team, with potential investors, customers, collaborators, our broader innovation community;
• Reinforcing our capacity in attracting partners, broaden the prospect of new collaborations across Europe and worldwide, thereby strengthening our market position;
• Exposing us to new investors within medtech and digital health, and helping to improve attractiveness of our investment case.
We saw an opportunity how AI and machine learning could be used to successfully analyze large amounts of data at expert-level performance. And we saw how remote patient monitoring of chronic lung and heart patients, producing large amounts of data, could benefit from technology like ours.
Medsensio offers a digital care solution which brings AI into screening, monitoring and predictions in chronic lung and heart disease management for improving patient outcomes and reducing cost. Our product is now ready for regulatory compliance under MDR and we are preparing for market launch in 2023.
WomenTechEU will provide access to mentoring and networks to support our female CEO in building a strong and gender balanced team, leading it through the early market phase. Furthermore, it will make Medsensio better prepared for realising its market and growth potential:
• Boosting our expertise in handling negotiations and closing accounts for establishing partnerships, profiling potential customers for an efficient sales process, refining our marketing and sales tactics;
• Expanding collaboration and streamlining communication in the team, with potential investors, customers, collaborators, our broader innovation community;
• Reinforcing our capacity in attracting partners, broaden the prospect of new collaborations across Europe and worldwide, thereby strengthening our market position;
• Exposing us to new investors within medtech and digital health, and helping to improve attractiveness of our investment case.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101114412 |
| Start date: | 01-06-2023 |
| End date: | 29-02-2024 |
| Total budget - Public funding: | - 75 000,00 Euro |
Cordis data
Original description
Medsensio was founded in 2017 as a spinout from a research project in health data analysis at UiT the Arctic University of Norway, classifying lung and heart sounds and additional parameters from Norway's largest population study known as the Tromsø study.We saw an opportunity how AI and machine learning could be used to successfully analyze large amounts of data at expert-level performance. And we saw how remote patient monitoring of chronic lung and heart patients, producing large amounts of data, could benefit from technology like ours.
Medsensio offers a digital care solution which brings AI into screening, monitoring and predictions in chronic lung and heart disease management for improving patient outcomes and reducing cost. Our product is now ready for regulatory compliance under MDR and we are preparing for market launch in 2023.
WomenTechEU will provide access to mentoring and networks to support our female CEO in building a strong and gender balanced team, leading it through the early market phase. Furthermore, it will make Medsensio better prepared for realising its market and growth potential:
• Boosting our expertise in handling negotiations and closing accounts for establishing partnerships, profiling potential customers for an efficient sales process, refining our marketing and sales tactics;
• Expanding collaboration and streamlining communication in the team, with potential investors, customers, collaborators, our broader innovation community;
• Reinforcing our capacity in attracting partners, broaden the prospect of new collaborations across Europe and worldwide, thereby strengthening our market position;
• Exposing us to new investors within medtech and digital health, and helping to improve attractiveness of our investment case.
Status
SIGNEDCall topic
HORIZON-EIE-2022-SCALEUP-02-02Update Date
31-07-2023
Images
No images available.
Geographical location(s)
